News

BRANFORD, CT — GeneSpark Diagnostics, a molecular diagnostics company in Branford, has created a portable, handheld rapid testing device called GeneSparkDx that can detect the virus that causes COVID-19, among many other pathogens. GeneSpark co-founder and chief scientific officer John Davidson said the biosciences company has created the "perfect tool to fight the Covid virus …

Continue reading "Branford BioMed Company Develops Handheld, Rapid COVID-19 Test"

HARTFORD—U.S. Senator Chris Murphy (D-Conn.) announced on Wednesday that innovator GeneSpark Diagnostics in Branford has been named “Innovator of the Month.” Founded in 2013 by two Connecticut natives, GeneSpark's goal has been to bring high quality molecular diagnostics for infectious diseases out of the laboratory and closer to the patient, including remote, rural, and underserved communities. GeneSpark has developed a …

Continue reading "Murphy Highlights Branford Innovator GeneSpark As “Murphy’s Innovator Of The Month”"

BRANFORD, Conn. (WTNH) — The fight to stop the spread of COVID-19 keeps being hampered by the fact that COVID-19 tests take days to come back from a lab. But one Branford company has a device that can deliver an accurate reading in just a few minutes. GeneSpark Diagnostics opened up in 2013 to make …

Continue reading "Branford Company Makes Medical Testing Device That Can Deliver COVID Results in Minutes"

BRANFORD, Conn.--(BUSINESS WIRE)--GeneSpark Diagnostics, Inc., a molecular diagnostic company located in Branford, Connecticut, announced that it has closed a $12.2 million Series B Preferred Stock financing with participation of current and new investors, including Connecticut Innovations, VC23, Leading Edge Ventures, and Parvizi Surgical. The financing was oversubscribed from the $10 million initially sought to be …

Continue reading "GeneSpark Diagnostics Closes Oversubscribed $12.2M Series B Preferred Stock Financing"

BRANFORD, Conn.--(BUSINESS WIRE)--GeneSpark Diagnostics, Inc. announced today that it was awarded a contract by the New York State Department of Health’s Wadsworth Center in conjunction with Health Research Inc. to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and is emerging as a public health threat. According to …

Continue reading "GeneSpark Diagnostics Awarded a Contract for Point-of-Care Detection of Candida auris"

BRANFORD, Conn.--(BUSINESS WIRE)--GeneSpark Diagnostics, Inc., today announced that the company and LabWare, Inc. agreed to enter into an exclusive partnership whereby LabWare will distribute GeneSpark's GeneSpark™ device as part of the LabWare’s Portable Disease Surveillance Lab kit in response to the COVID-19 pandemic. LabWare’s kit includes a mobile hot spot and a tablet computer connected …

Continue reading "GeneSpark Diagnostics and LabWare Formed an Exclusive Partnership for Point-of-Care COVID-19 Molecular Test and Real-time Data Reporting"

BRANFORD, Conn.--(BUSINESS WIRE)--GeneSpark Diagnostics, Inc., an innovative developer of rapid, portable, and Point-of-Care diagnostics, today announced that the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded GeneSparkTM the Second Option of a contract to develop a molecular diagnostic platform that can be used by the company to …

Continue reading "BARDA Funds GeneSpark Diagnostics’ Multi-Target Platform Technology Development and a New Contract for Point-of-Care COVID-19 Molecular Test"